Clinical Trial News and Research

RSS

Focused ultrasound technology safe, effective in treating patients with tremor-dominant Parkinson's

The Focused Ultrasound Foundation today announced a new clinical trial investigating the use of focused ultrasound technology in treating patients with tremor-dominant Parkinson's disease.

25 Oct 2012

Study finds decline in inpatient mortality rate for upper gastrointestinal hemorrhage in the U.S.

The number of patients dying from upper gastrointestinal bleeding has decreased over the past two decades, a result researchers attribute to the advances in medical and endoscopic therapies introduced over the past 20 years, according to a report unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas.

24 Oct 2012

SUNY Downstate to join Neurological Emergencies Treatment Trials network

SUNY Downstate Medical Center has been selected by the National Institutes of Health (NIH) to join the Neurological Emergencies Treatment Trials (NETT) network, which is dedicated to improving emergency care for neurological injuries that require immediate care, such as stroke, seizures, and traumatic brain injury, as well as other illnesses affecting the brain, spinal cord, and peripheral nervous system.

24 Oct 2012

New project aims to devise programs that help reduce risk of cancer

Most people know that smoking, a bad diet, and physical inactivity can lead to catastrophic personal health consequences, including cancer. Yet millions continue to smoke, eat poorly, and fail to get enough exercise.

24 Oct 2012

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

23 Oct 2012

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Sickle cell disease is a devastating hereditary condition that affects millions of people, particularly those in West and Central Africa as well as people of African descent in the United States, Europe and South America.

23 Oct 2012

Financial environment presents opportunities as well as challenges

Leading biotechnology executive Dr Deborah Rathjen has called on the industry to look at the opportunities that exist in a post-GFC environment, not just to focus on the negatives.

23 Oct 2012

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns.

23 Oct 2012

$Ustekinumab success in refractory Crohn’s disease$

Ustekinumab success in refractory Crohn’s disease

Patients with Crohn’s disease who have failed to respond adequately to anti–tumor necrosis factor treatment may benefit from the monoclonal antibody ustekinumab, results of a double-blind, placebo-controlled trial suggest.

22 Oct 2012

Initiation of dinaciclib Phase 2b/3 CLL trial triggers $2M milestone payment from Merck

Ligand Pharmaceuticals Incorporated today announced that it will receive a $2 million milestone payment from Merck, known as MSD outside the United States and Canada, under the terms of a development and license collaboration for the development of dinaciclib.

22 Oct 2012

MID commences treatment in Permaseal cardiac access and closure technology clinical trial

Micro Interventional Devices, Inc., an emerging cardiovascular medical device company, announced today that the first patient has been treated using its self-sealing, cardiac access and closure technology, Permaseal. The patient is the first to be enrolled in the company's STASIS clinical trial that has commenced in Europe.

22 Oct 2012

PLoS ONE publishes review of AntiViral-HyperActivation Limiting Therapeutics clinical trial

ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE.

22 Oct 2012

Rhythm presents RM-131 Phase 1 clinical trial results for diabetic gastroparesis at ACG 2012

Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.

22 Oct 2012

Clinical trial to study immunosuppressant tacrolimus against generics

A new study at the University of Cincinnati seeks to end the questions over generic-vs.-brand for a common immunosuppressive drug for transplant patients, tacrolimus.

20 Oct 2012

Brain Injury Research Center of Mount Sinai receives fund to research on TBI

The Brain Injury Research Center of Mount Sinai has received two prestigious grants totaling $6.65 million to fund research on traumatic brain injury over the next five years.

20 Oct 2012

ACT TIL therapy effective in treating metastatic melanoma

Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL).

19 Oct 2012

Quick, cheap eye scan can predict brain damage in people with multiple sclerosis

An inexpensive, five-minute eye scan can accurately assess the amount of brain damage in people with the debilitating autoimmune disorder multiple sclerosis (MS), and offer clues about how quickly the disease is progressing, according to results of two Johns Hopkins studies.

19 Oct 2012

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San Diego, School of Medicine.

18 Oct 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012

Study examines long-term affect of multivitamins on major chronic diseases

A daily multivitamin can help a man reduce his risk of cancer, according to new research from Brigham and Women's Hospital.

18 Oct 2012

Clinical Trial News and Research

Focused ultrasound technology safe, effective in treating patients with tremor-dominant Parkinson's

Study finds decline in inpatient mortality rate for upper gastrointestinal hemorrhage in the U.S.

SUNY Downstate to join Neurological Emergencies Treatment Trials network

New project aims to devise programs that help reduce risk of cancer

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Financial environment presents opportunities as well as challenges

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

Ustekinumab success in refractory Crohn’s disease

Initiation of dinaciclib Phase 2b/3 CLL trial triggers $2M milestone payment from Merck

MID commences treatment in Permaseal cardiac access and closure technology clinical trial

PLoS ONE publishes review of AntiViral-HyperActivation Limiting Therapeutics clinical trial

Rhythm presents RM-131 Phase 1 clinical trial results for diabetic gastroparesis at ACG 2012

Clinical trial to study immunosuppressant tacrolimus against generics

Brain Injury Research Center of Mount Sinai receives fund to research on TBI

ACT TIL therapy effective in treating metastatic melanoma

Quick, cheap eye scan can predict brain damage in people with multiple sclerosis

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Study examines long-term affect of multivitamins on major chronic diseases

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer